他汀類藥物和血管緊張素Ⅱ受體拮抗劑治療慢性阻塞性肺疾病的研究_《華西醫學》

作者：

陳維永 ,  柯華

成都市第七人民醫院呼吸科（成都，610021）;

關鍵詞：

他汀類藥物血管緊張素Ⅱ受體拮抗劑慢性阻塞性肺疾病

DOI：

CNKI: 51-1356/R.20120214.1341.027

視頻：

導出 下載 收藏 掃碼 引用

摘要 全文 圖表 視頻 參考文獻 施引文獻 補充材料

慢性阻塞性肺疾病（COPD）以氣道、肺實質和肺血管的慢性炎癥為特征，近年來發現他汀類藥物除降脂作用外，還可改善COPD患者的癥狀及預后。血管緊張素Ⅱ受體拮抗劑，能抑制肺血管缺氧性收縮以及慢性缺氧時血管的重建。能防止COPD患者肺動脈高壓的病程進展及肺功能的下降。兩者合用有協調作用，不僅能緩解COPD患者的癥狀，還能延緩COPD的進程，降低死亡率。

引用本文： 陳維永,柯華. 他汀類藥物和血管緊張素Ⅱ受體拮抗劑治療慢性阻塞性肺疾病的研究. 華西醫學, 2012, 27(2): 300-303. doi: CNKI: 51-1356/R.20120214.1341.027 復制

1.	中華醫學會呼吸病學分會慢性阻塞性肺疾病. 慢性阻塞性肺疾病診療指南(2007年修訂版)[J]. 中華結核和呼吸雜志, 2007, 30(1): 8-17.
2.	Gan WQ, Man SF, Senthilselvan A, et al. Associasion between chronic obstructive pulmonary disease and systemic inflammation:a systematic review and a meta-analysis[J]. Thorax, 2004, 59(7): 574-580.
3.	Garrod R, Marshall J, Barley E, et al.The relationship between inflammatory markers and disability in chronic obstructive pulmonary disease (COPD) [J]. Prim Care Respir J, 2007, 16(4): 236-240.
4.	Fessler MB, Young SK, Jeyaseelan S, et al. A role for hydroxyl-methylglutaryl cocenzyme a reductase in pulmonary inflammation and host defense[J]. Am J Respir Crit Care Med, 2005, 171(6): 606-615.
5.	丁艷苓, 姚婉貞. 慢性阻塞性肺疾病與哮喘氣道炎癥的研究[J]. 中國呼吸與危重監護雜志, 2004, 3(6): 410-412, 415.
6.	Ou XM, Wang BD, Wen FQ, et al. Simvastatin attenuates lipopolysaccharide-induced airway mucus hypersecretion in rats[J]. Chin Med J (Engl), 2008, 121(17): 1680-1687.
7.	Ghavami S, Mutawe MM, Hauff K, et al. Statin-triggered cell death in primary human lung mesenchymal cells involves p53-PUMA and release of Smac and Omi but not cytochrome[J]. Biochim Biophys Acta, 2010, 1803(4): 452-467.
8.	Hothersall E, McSharry C, Tomo NC. Potential therapeutic role for statins in respiratory disease[J]. Thorox, 2006, 61(8): 729-734.
9.	Morimoto K, Janseen WJ, Fessler MB, et al. Lovastatin enhances clearance of apoptotic cells (efferocytosis) with implications for chronic obstructive pulmonary disease[J]. J Immunol, 2006, 176(12): 7657-7665.
10.	Kim DY, Ryu SY, Lim JE, et al. Anti-inflammatory mechanism of simvastin in mouse allergic asthma model[J]. Eur J Pharmacol, 2007, 557(1): 76-86.
11.	Cheelo M, Anselmi A, Spadaccio C, et al. simvastin increases neutrophil apoptosis and reduces inflammatory reaction after coronary surgery[J]. Ann Thorac Surg, 2007, 83(4): 1374-1380.
12.	Lee TM, Lin MS, Chang NC. Usefulness of C-reactive protein and interleukin-6 as predictors of outcomes in patients with chronic obstructive pulmonary disease receiving pravastatin[J]. Am J Cardiol, 2008, 101(4): 530-535.
13.	Kedissi JI, Younis WG, Chbier EA, et al. The use of statins and lung function incurrent and former smokers[J]. Chest, 2007, 132(6): 1764-1767.
14.	Alexeeff SE, Litonjua AA, Sparrow D, et al. Statin use reduces decline in lung function:VA Normative Aging Study[J]. Am J Respir Crit Care Med, 2007, 176(8): 742-747.
15.	夏書月, 康健, 何巍, 等. 辛伐他汀對COPD急性加重期患者誘導痰血管內皮生長因子水平和肺功能的影響[J]. 中國呼吸與危重監護雜志, 2010, 9(3): 295-297.
16.	Nishimura T, Faul JL, Berry GJ, et al. Simvastatin attenuates smooth muscle neointimal preliferation and pulmonary hypertension in rats[J]. Am J Respir Crit Care Med, 2002, 166(10): 1403-1408.
17.	Nishimura T, Vaszar LT, Faul JL, et al. Simvastatin rescues rats from fatal pulmonary hypertension by inducing apoptosis of neointimal smooth muscle cells[J]. Circulation, 2003, 108(13): 1640-1645.
18.	Syseth V, Brekke PH, Smith P, et al. Statin use is associated with reduced mortality in COPD[J]. Eur Respir J, 2007, 29(2): 279-283.
19.	van Gestel YR, Hoeks SE, Sin DD, et al. Effect of statin therapy on comparison of those with versus without associated chronic obstructive pulmonary disease[J]. Am J Cardiol, 2008, 102(2): 192-196.
20.	Mancini GB, Etminan M, Zhang B, et al. Reduction of morbidity and mortality by statins,angiotensin-converting enzyme inhibitors,and angiotensin receptor blockers in patients with chronic obstructive pulmonary disease[J]. J Am Coll Cardiol, 2006, 47(12): 2544-2560.
21.	Phillips MI, Kagiyama S. Angiotensin I as a proinflammatory mediator[J]. Curr Opin lnvestig Drugs, 2002, 3(4): 569-577.
22.	Suzuki Y, Ruiz-Ortega M, Lorenzo O, et a1. Inflammation and angiotensinⅡ[J]. Int J Biochem Cell Biol, 2003, 35(6): 881-900.
23.	Ruiz-Ortega M, Lorenzo O, Suzuki Y, et a1. Prolnflammatory actions of angiotensins[J]. Curr Opin Nephrol Hypertens, 2001, 10(3): 321-329.
24.	Elferink JG, de Koster BM. The stimulation of human neutrophil migration by angiotensin I: its dependence on Caand the involvement of cyclic GMP[J]. Br J Pharmacol, 1997, 121(4): 643-648.
25.	Raiden S, Nahmod K, Namod V, et a1. Nonpeptide antagonists of AT1 receptor for angiotensin Ⅱ delay the onset of acute respiratory distress syndrome[J]. J Pharmacol Exp Ther, 2002, 303(1): 45-51.
26.	Hernández-Presa MA, Bustos C, Ortego M, et a1. ACE inhibitor quinapril reduces the arterial expression of NF-kappaB-dependent prolnflammatory factors but not of collagenI in a rabbit model of atherosclerosis[J]. Am J Pathol, 1998, 153(6): 1825-1837.
27.	Gräfe M, Auch-Schwelk W, Zakrzewicz A, et a1. AngiotensinⅡ-induced leukocytes adhesion on human coronary endothelial cells is mediated by E-selection[J]. Circ Res, 1997, 81(5): 804-811.
28.	Vlahakos DV, Marathias KP, Kosmas EN. Losartan reduces hematocrit in patients with chronic obstructive pulmonary disease and secondary erythrocytosis[J]．Ann Intern Med，2001, 134(5): 426-427．.
29.	Hussein O, Shneider J, Rosenblat M, et al. Valsartan therapy has additive anti-oxidative efect to that of fluvastatin therapy against low-density lipoprotein oxidation: studies in hyperholesterolemic and hypertensive patients[J]. J Cardiovasc Pharmacol, 2002, 40(1): 28-34.
30.	Horiuchi M, Cui TX, Li Z, et a1. Fluvastatin enhances the inhibit-tory effects of a selective angiotensinⅡ Type 1 receptor blocker Valsartan On vascular neointimal formation[J]. Circulation, 2003, 107(1): 106-112.
31.	Wassmann S, Laufs U, Bäumer AT, et a1. Inhibition of geranylgeranylation reduces angiotensinⅡ mediated free radical production in vascular smooth muscle cells:involvement of angiotensin ATl receptor expression and Racl GTPase[J]. Mol Pharmacol, 2001, 59(3): 646-654.

1. 　中華醫學會呼吸病學分會慢性阻塞性肺疾病. 慢性阻塞性肺疾病診療指南(2007年修訂版)[J]. 中華結核和呼吸雜志, 2007, 30(1): 8-17.
2. 　Gan WQ, Man SF, Senthilselvan A, et al. Associasion between chronic obstructive pulmonary disease and systemic inflammation:a systematic review and a meta-analysis[J]. Thorax, 2004, 59(7): 574-580.
3. 　Garrod R, Marshall J, Barley E, et al.The relationship between inflammatory markers and disability in chronic obstructive pulmonary disease (COPD) [J]. Prim Care Respir J, 2007, 16(4): 236-240.
4. 　Fessler MB, Young SK, Jeyaseelan S, et al. A role for hydroxyl-methylglutaryl cocenzyme a reductase in pulmonary inflammation and host defense[J]. Am J Respir Crit Care Med, 2005, 171(6): 606-615.
5. 　丁艷苓, 姚婉貞. 慢性阻塞性肺疾病與哮喘氣道炎癥的研究[J]. 中國呼吸與危重監護雜志, 2004, 3(6): 410-412, 415.
6. 　Ou XM, Wang BD, Wen FQ, et al. Simvastatin attenuates lipopolysaccharide-induced airway mucus hypersecretion in rats[J]. Chin Med J (Engl), 2008, 121(17): 1680-1687.
7. 　Ghavami S, Mutawe MM, Hauff K, et al. Statin-triggered cell death in primary human lung mesenchymal cells involves p53-PUMA and release of Smac and Omi but not cytochrome[J]. Biochim Biophys Acta, 2010, 1803(4): 452-467.
8. 　Hothersall E, McSharry C, Tomo NC. Potential therapeutic role for statins in respiratory disease[J]. Thorox, 2006, 61(8): 729-734.
9. 　Morimoto K, Janseen WJ, Fessler MB, et al. Lovastatin enhances clearance of apoptotic cells (efferocytosis) with implications for chronic obstructive pulmonary disease[J]. J Immunol, 2006, 176(12): 7657-7665.
10. 　Kim DY, Ryu SY, Lim JE, et al. Anti-inflammatory mechanism of simvastin in mouse allergic asthma model[J]. Eur J Pharmacol, 2007, 557(1): 76-86.
11. 　Cheelo M, Anselmi A, Spadaccio C, et al. simvastin increases neutrophil apoptosis and reduces inflammatory reaction after coronary surgery[J]. Ann Thorac Surg, 2007, 83(4): 1374-1380.
12. 　Lee TM, Lin MS, Chang NC. Usefulness of C-reactive protein and interleukin-6 as predictors of outcomes in patients with chronic obstructive pulmonary disease receiving pravastatin[J]. Am J Cardiol, 2008, 101(4): 530-535.
13. 　Kedissi JI, Younis WG, Chbier EA, et al. The use of statins and lung function incurrent and former smokers[J]. Chest, 2007, 132(6): 1764-1767.
14. 　Alexeeff SE, Litonjua AA, Sparrow D, et al. Statin use reduces decline in lung function:VA Normative Aging Study[J]. Am J Respir Crit Care Med, 2007, 176(8): 742-747.
15. 　夏書月, 康健, 何巍, 等. 辛伐他汀對COPD急性加重期患者誘導痰血管內皮生長因子水平和肺功能的影響[J]. 中國呼吸與危重監護雜志, 2010, 9(3): 295-297.
16. 　Nishimura T, Faul JL, Berry GJ, et al. Simvastatin attenuates smooth muscle neointimal preliferation and pulmonary hypertension in rats[J]. Am J Respir Crit Care Med, 2002, 166(10): 1403-1408.
17. 　Nishimura T, Vaszar LT, Faul JL, et al. Simvastatin rescues rats from fatal pulmonary hypertension by inducing apoptosis of neointimal smooth muscle cells[J]. Circulation, 2003, 108(13): 1640-1645.
18. 　Syseth V, Brekke PH, Smith P, et al. Statin use is associated with reduced mortality in COPD[J]. Eur Respir J, 2007, 29(2): 279-283.
19. 　van Gestel YR, Hoeks SE, Sin DD, et al. Effect of statin therapy on comparison of those with versus without associated chronic obstructive pulmonary disease[J]. Am J Cardiol, 2008, 102(2): 192-196.
20. 　Mancini GB, Etminan M, Zhang B, et al. Reduction of morbidity and mortality by statins,angiotensin-converting enzyme inhibitors,and angiotensin receptor blockers in patients with chronic obstructive pulmonary disease[J]. J Am Coll Cardiol, 2006, 47(12): 2544-2560.
21. 　Phillips MI, Kagiyama S. Angiotensin I as a proinflammatory mediator[J]. Curr Opin lnvestig Drugs, 2002, 3(4): 569-577.
22. 　Suzuki Y, Ruiz-Ortega M, Lorenzo O, et a1. Inflammation and angiotensinⅡ[J]. Int J Biochem Cell Biol, 2003, 35(6): 881-900.
23. 　Ruiz-Ortega M, Lorenzo O, Suzuki Y, et a1. Prolnflammatory actions of angiotensins[J]. Curr Opin Nephrol Hypertens, 2001, 10(3): 321-329.
24. 　Elferink JG, de Koster BM. The stimulation of human neutrophil migration by angiotensin I: its dependence on Caand the involvement of cyclic GMP[J]. Br J Pharmacol, 1997, 121(4): 643-648.
25. 　Raiden S, Nahmod K, Namod V, et a1. Nonpeptide antagonists of AT1 receptor for angiotensin Ⅱ delay the onset of acute respiratory distress syndrome[J]. J Pharmacol Exp Ther, 2002, 303(1): 45-51.
26. 　Hernández-Presa MA, Bustos C, Ortego M, et a1. ACE inhibitor quinapril reduces the arterial expression of NF-kappaB-dependent prolnflammatory factors but not of collagenI in a rabbit model of atherosclerosis[J]. Am J Pathol, 1998, 153(6): 1825-1837.
27. 　Gräfe M, Auch-Schwelk W, Zakrzewicz A, et a1. AngiotensinⅡ-induced leukocytes adhesion on human coronary endothelial cells is mediated by E-selection[J]. Circ Res, 1997, 81(5): 804-811.
28. 　Vlahakos DV, Marathias KP, Kosmas EN. Losartan reduces hematocrit in patients with chronic obstructive pulmonary disease and secondary erythrocytosis[J]．Ann Intern Med，2001, 134(5): 426-427．.
29. 　Hussein O, Shneider J, Rosenblat M, et al. Valsartan therapy has additive anti-oxidative efect to that of fluvastatin therapy against low-density lipoprotein oxidation: studies in hyperholesterolemic and hypertensive patients[J]. J Cardiovasc Pharmacol, 2002, 40(1): 28-34.
30. 　Horiuchi M, Cui TX, Li Z, et a1. Fluvastatin enhances the inhibit-tory effects of a selective angiotensinⅡ Type 1 receptor blocker Valsartan On vascular neointimal formation[J]. Circulation, 2003, 107(1): 106-112.
31. 　Wassmann S, Laufs U, Bäumer AT, et a1. Inhibition of geranylgeranylation reduces angiotensinⅡ mediated free radical production in vascular smooth muscle cells:involvement of angiotensin ATl receptor expression and Racl GTPase[J]. Mol Pharmacol, 2001, 59(3): 646-654.

上一篇
特發性肺含鐵血黃素沉著癥一例
下一篇
乳腺癌保乳術后加速部分乳腺放射治療的臨床應用現狀

《華西醫學》

他汀類藥物和血管緊張素Ⅱ受體拮抗劑治療慢性阻塞性肺疾病的研究

摘要 全文 圖表 視頻 參考文獻 施引文獻 補充材料

上一篇

下一篇

Format

Content

《華西醫學》

他汀類藥物和血管緊張素Ⅱ受體拮抗劑治療慢性阻塞性肺疾病的研究

摘要 全文 圖表 視頻 參考文獻 施引文獻 補充材料

上一篇

下一篇

Format

Content

摘要全文圖表視頻參考文獻施引文獻補充材料